Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate
Authors:
- Alan PollackAPAlan Pollack
- Lewis G SmithLSLewis G Smith
- 1 July 1999
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 44 (4) , 809-819
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Prognostic factors for clinically localized prostate carcinomaCancer, 1997
- Carcinoma of the prostate: a model for management under impending health care system reform. 1994 RSNA annual oration in radiation oncology.Radiology, 1995
- Control of Prostate Cancer with Radiotherapy: Long-Term ResultsJournal of Urology, 1994
- Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapyCancer, 1993
- Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapyCancer, 1993
- Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostateUrology, 1993
- Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: FollowupJournal of Urology, 1993
- Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-upRadiotherapy and Oncology, 1990
- Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiationCancer, 1987
- Hormone therapy in prostatic cancerThe American Journal of Medicine, 1956